PA · EL.PA · MEDICAL - INSTRUMENTS & SUPPLIES
EssilorLuxottica S.A. (EL.PA) intrinsic value and stock valuation
$174.60as of 2026-11-21 · Mkt cap 80.55B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
EssilorLuxottica S.A. DCF and intrinsic value
InvestorsCraft values EL.PA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from EL.PA’s statements →
EssilorLuxottica S.A. Graham Number
Graham Number: $98.81d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $28.5B | $26.5B | $25.4B | $24.5B | $19.8B |
| Operating income | $3.36B | $3.45B | $3.18B | $3.26B | $2.57B |
| Net income | $2.32B | $2.36B | $2.29B | $2.15B | $1.45B |
| EPSd | $4.98M | $5.13M | $5.08M | $4.83M | $3.25M |
| Operating cash flow | $5.29B | $4.87B | $4.86B | $4.78B | $4.55B |
| Capital expenditure | -$-1.53B | -$-1.52B | -$-1.53B | -$-1.57B | -$-1.03B |
| Free cash flow | $3.77B | $3.35B | $3.33B | $3.21B | $3.52B |
| Total assets | $63.9B | $64.3B | $60.5B | $60.6B | $59.4B |
| Total debt | $17.1B | $13.2B | $11.7B | $12.2B | $13B |
| Net debt | $13.5B | $11B | $9.1B | $10.4B | $11.4B |
| Total equity | $39.5B | $41B | $38.9B | $38.1B | $35.9B |
| Cash and short-term investments | $3.54B | $2.25B | $2.56B | $1.99B | $3.34B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $28.5B | $26.5B | $25.4B | $24.5B | $19.8B |
| Cost of revenue | $11.2B | $9.7B | $9.35B | $8.9B | $7.54B |
| Gross profit | $17.3B | $16.8B | $16B | $15.6B | $12.3B |
| Research and development expenses | $664M | $630M | $593M | $600M | $579M |
| Selling, general and administrative expenses | $13.2B | $12.5B | $12.1B | $11.7B | $9.24B |
| Other expenses | $0.00 | $197M | $228M | $60M | $66M |
| Operating expenses | $13.9B | $13.4B | $12.9B | $12.3B | $9.71B |
| Cost and expenses | $25.1B | $23.1B | $22.2B | $21.2B | $17.2B |
| Interest income | $0.00 | $5M | $64M | $26M | $30M |
| Interest expense | $239M | $165M | $198M | $156M | $141M |
| Depreciation and amortization | $3.11B | $3.1B | $2.95B | $2.92B | $2.39B |
| Ebitda | $6.47B | $6.55B | $6.18B | $6.1B | $4.71B |
| Operating income | $3.36B | $3.45B | $3.18B | $3.26B | $2.57B |
| Total other income/expenses, net | -$-166M | -$-157M | -$-141M | -$-232M | -$-126M |
| Income before tax | $3.2B | $3.29B | $3.04B | $3.03B | $2.18B |
| Income tax expense | $752M | $800M | $609M | $751M | $583M |
| Net income | $2.32B | $2.36B | $2.29B | $2.15B | $1.45B |
| Weighted average shares outstanding | $459M | $453.9M | $448.1M | $442.1M | $438.8M |
| Weighted average diluted shares outstanding | $464.7M | $460M | $450.8M | $445.7M | $445.5M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $3.54B | $2.25B | $2.56B | $1.99B | $3.34B |
| Net receivables | $3.77B | $3.26B | $2.97B | $2.73B | $2.39B |
| Inventory | $3.54B | $3.15B | $2.75B | $2.91B | $2.53B |
| Total current assets | $12B | $10B | $9.72B | $8.64B | $9.19B |
| Property, plant and equipment, net | $9.05B | $9.17B | $8.25B | $7.76B | $7.14B |
| Goodwill and intangible assets | $40.8B | $43B | $41.3B | $73.6B | $70.8B |
| Long-term investments | $88M | $1.03B | $80M | $519M | $387M |
| Total non-current assets | $51.9B | $54.2B | $50.8B | $51.9B | $50.2B |
| Total assets | $63.9B | $64.3B | $60.5B | $60.6B | $59.4B |
| Accounts payable | $2.88B | $2.66B | $2.38B | $2.3B | $2.22B |
| Short-term debt | $4.93B | $3.41B | $2.7B | $2.01B | $1.87B |
| Deferred revenue | $0.00 | $0.00 | $209M | $222M | $179M |
| Total current liabilities | $12.2B | $10.6B | $9.74B | $8.89B | $8.93B |
| Long-term debt | $12.1B | $9.8B | $8.96B | $10.2B | $11.1B |
| Deferred revenue, non-current | $0.00 | $21M | $15M | $27M | $27M |
| Total non-current liabilities | $12.3B | $12.7B | $11.9B | $13.5B | $14.6B |
| Capital lease obligations | $2.65B | $3.65B | $3.24B | $3.18B | $3.07B |
| Total liabilities | $24.4B | $23.3B | $21.6B | $22.4B | $23.5B |
| Common stock | $83M | $82M | $82M | $81M | $80M |
| Retained earnings | $0.00 | $2.36B | $15.4B | $13.4B | $12.7B |
| Accumulated other comprehensive income (loss) | $0.00 | $1.17B | $212M | $1.23B | $139M |
| Total equity | $39.5B | $41B | $38.9B | $38.1B | $35.9B |
| Total investments | $88M | $1.03B | $81M | $752M | $2.13B |
| Total debt | $17.1B | $13.2B | $11.7B | $12.2B | $13B |
| Net debt | $13.5B | $11B | $9.1B | $10.4B | $11.4B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $2.32B | $2.49B | $2.29B | $2.15B | $1.45B |
| Depreciation and amortization | $3.11B | $3.1B | $2.97B | $2.92B | $2.39B |
| Stock-based compensation | $0.00 | $162M | $220M | $191M | $160M |
| Change in working capital | -$-468M | -$-697M | -$-427M | -$-356M | $329M |
| Accounts receivable | $0.00 | -$-133M | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash provided by operating activities | $5.29B | $4.87B | $4.86B | $4.78B | $4.55B |
| Investments in property, plant and equipment | -$-1.53B | -$-1.52B | -$-1.53B | -$-1.57B | -$-1.03B |
| Acquisitions, net | -$-982M | -$-1.76B | -$-114M | -$-1.62B | -$-7.13B |
| Net cash used for investing activities | -$-2.64B | -$-3.62B | -$-1.72B | -$-3.29B | -$-8.13B |
| Common stock issued | $36M | $35M | $34M | $37M | $34M |
| Common stock repurchased | -$-376M | -$-274M | -$-271M | -$-431M | -$-317M |
| Dividends paid | -$-547M | -$-1.16B | -$-487M | -$-454M | -$-138M |
| Net cash used for financing activities | -$-971M | -$-1.65B | -$-2.36B | -$-2.91B | -$-1.97B |
| Net change in cash | $1.29B | -$-307M | $598M | $168M | -$-3.1B |
| Cash at end of period | $3.54B | $2.25B | $2.56B | $1.76B | $1.59B |
| Operating cash flow | $5.29B | $4.87B | $4.86B | $4.78B | $4.55B |
| Capital expenditure | -$-1.53B | -$-1.52B | -$-1.53B | -$-1.57B | -$-1.03B |
| Free cash flow | $3.77B | $3.35B | $3.33B | $3.21B | $3.52B |
Line items
Line items
Line items
About EssilorLuxottica S.A.
EssilorLuxottica Société anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in North America, Europe, Latin America, Asia, Oceania, and Africa. It operates in five segments: Wholesale, Retail, Lenses and Optical Instruments, Equipment, and Sunglasses and Readers. The Wholesale segment engages in the manufacture and wholesale distribution of luxury and sports eyewear. The Retail segment retails luxury and sports eyewear. The Lenses and Optical Instruments segment offers lenses and small equipment, including Varilux progressive lenses; Crizal antireflective, anti-smudge, and antistatic lenses; Transitions photochromic lenses; Eyezen lenses for users of computers, tablets, smartphones, and other connected devices; Xperio polarized sun lenses; and Nikon and Kodak corrective lens brands. It also provides lens edging and mounting instruments for opticians and prescription laboratories; optometry instruments for eye care professionals, schools, occupational medicine centers, military, and other institutions; and Transitions Signature Gen 8 photochromic lens, as well as develops solutions for online sales of optical products. The Equipment segment offers digital surfacing machines and lens coating machines to prescription laboratories, integrated optical chains, and lens manufacturers. The Sunglasses and Readers segment provides non-prescription sunglasses and reading glasses under the Foster Grant, Gargoyles, Magnivision, Corinne McCormack, Monkey Monkey, Ryders Eyewear, and SolarShield brands; Reebok, Steve Madden, Betsey Johnson, Nine West, Dockers, French Connection, Ironman, Rawlings, Bodyglove, Panama Jack, Marvel, and Disney; Bolon, Molsion, Qina, and Prosun brands; and Mujosh and Aojo brands. It has a network of 490 prescription laboratories and edging-mounting facilities. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.
- CEO
- Francesco Milleri
- Employees
- 153.5K
- Beta
- 0.54
Included in
Explore
Frequently asked questions
What is the intrinsic value of EssilorLuxottica S.A. (EL.PA)?
InvestorsCraft does not currently publish an intrinsic value for EL.PA. How the IC value is calculated.
Is EL.PA undervalued?
InvestorsCraft does not publish an undervaluation signal for EL.PA at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.